BrainFutures

Data updated July 2, 2026

United States

1 Event

BrainFutures is a national US nonprofit based in Baltimore, Maryland, that bridges research, innovation, and practice to advance evidence-based brain interventions. It serves policymakers, providers, funders, and the public by producing evidence-based issue briefs, recommendations, educational resources, and stakeholder convenings focused on brain health and recovery outcomes.

In psychedelic medicine, BrainFutures is explicit and active: it launched a psychedelic-assisted therapy initiative in 2021 to support policy-oriented research, coalition building, and education for policymakers, healthcare providers, payers, and the public. Its current work includes professional practice guidelines, psychedelic access pathway research, coding and reimbursement guidance, parity-focused access work, and a survey on psychedelic therapy curricula in academia. It positions itself as a bridge to equitable, system-ready access and a convenor for multi-stakeholder collaboration on regulation, training, reimbursement, and implementation.

ProfessionalOnlineFreeAcademic programmeContinuing educationOtherLicensed cliniciansResearchersOther

Blossom’s read

BrainFutures does not read as a course provider in the usual commercial sense so much as a policy-and-practice non-profit trying to shape the ecosystem around psychedelic-assisted therapy. Its psychedelic work is best understood as field-building: guidelines, access pathways, academic curricula support, convenings, and reimbursement conversations, rather than a standalone practitioner school. That makes it most useful for clinicians, educators, and systems people who want a sober, evidence-led orientation to where the field is heading, and it has credible lineage through named collaborations with the American Psychedelic Practitioners Association and academic leaders.

Who BrainFutures is for

Best suited to healthcare professionals, educators, policy and payer stakeholders, and academics who want a structured overview of psychedelic-assisted therapy rather than hands-on skills training. It may also suit clinicians or researchers looking to understand emerging standards, access pathways, and workforce development.

Prerequisites

No formal entry prerequisites were clearly stated for the materials surfaced. The academic-curriculum toolkit and convenings are aimed at educators and institutional leaders, while the professional practice guidelines are framed for mental health providers.

Accreditation & recognition

BrainFutures has at least one older activity that was jointly provided under ACCME/CME Outfitters and had Johns Hopkins School of Education continuing education approval, but that appears to relate to BrainFutures 2017 generally, not specifically the psychedelic initiative. For the psychedelic programme itself, the strongest source-backed claim is that BrainFutures co-published Professional Practice Guidelines with APPA; I found no evidence that BrainFutures itself offers an accredited certification, CME, or CE-bearing psychedelic training course.

Cost

I found no published tuition or fee information for the psychedelic-related materials. The visible offerings are mostly reports, guidelines, toolkits, convenings, and educational resources, which appear to be distributed as organisational resources rather than sold as a course package.

What you walk away with

Learners or readers should come away with an understanding of proposed professional standards, the elements of psychedelic-assisted therapy, access pathways, and how higher-education curricula might be built. The most concrete outputs are policy and practice literacy, not a recognised practitioner credential.